• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Otonomy Inc. (Amendment)

    2/9/23 11:47:09 AM ET
    $OTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OTIC alert in real time by email
    SC 13G/A 1 p23-0710sc13ga.htm OTONOMY, INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*
     

    Otonomy, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    68906L105

    (CUSIP Number)
     

    December 31, 2022

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 10 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 68906L10513G/APage 2 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Partners, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

     

     

    CUSIP No. 68906L10513G/APage 3 of 10 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Partners GP, L.L.C.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

     

     

    CUSIP No. 68906L10513G/APage 4 of 10 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Advisors, L.L.C.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

     

     

    CUSIP No. 68906L10513G/APage 5 of 10 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Robert Atchinson

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

     

     

    CUSIP No. 68906L10513G/APage 6 of 10 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Phillip Gross

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

     

     

    CUSIP No. 68906L10513G/APage 7 of 10 Pages

     

     

    Item 1(a). NAME OF ISSUER
      The name of the issuer is Otonomy, Inc. (the "Company").
       

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
      The Company's principal executive offices are located at 4796 Executive Drive, San Diego, California 92121.
       

     

    Item 2(a). NAME OF PERSON FILING
      This statement is filed by:
       
      (i) Adage Capital Partners, L.P., a Delaware limited partnership ("ACP") with respect to the shares of Common Stock directly owned by it;
       
      (ii) Adage Capital Partners GP, L.L.C., a limited liability company organized under the laws of the State of Delaware ("ACPGP"), as general partner of ACP with respect to the shares of Common Stock directly owned by ACP;
       
      (iii) Adage Capital Advisors, L.L.C., a limited liability company organized under the laws of the State of Delaware ("ACA"), as managing member of ACPGP, general partner of ACP, with respect to the shares of Common Stock directly owned by ACP;
       
      (iv) Robert Atchinson ("Mr. Atchinson"), as managing member of ACA, managing member of ACPGP, general partner of ACP with respect to the shares of Common Stock directly owned by ACP; and
       
      (v) Phillip Gross ("Mr. Gross"), as managing member of ACA, managing member of ACPGP, general partner of ACP with respect to the shares of Common Stock directly owned by ACP.
       
      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."  Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.
       
      The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.
       

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
      The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.
       

     

    Item 2(c). CITIZENSHIP
      ACP is a limited partnership organized under the laws of the State of Delaware.  ACPGP and ACA are limited liability companies organized under the laws of the State of Delaware.  Messrs. Gross and Atchinson are citizens of the United States.
       

     

     

    CUSIP No. 68906L10513G/APage 8 of 10 Pages

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
      Common Stock, par value $0.001 per share (the "Common Stock").
       

     

    Item 2(e). CUSIP NUMBER
      68906L105
       

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
      (g) ¨ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).
      If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: Not applicable.
             

     

    Item 4. OWNERSHIP
      A. Adage Capital Partners, L.P., Adage Capital Partners GP, L.L.C. and Adage Capital Advisors, L.L.C.
        (a) Amount beneficially owned:  0
        (b) Percent of class:  0%.  
        (c) (i) Sole power to vote or direct the vote:  0
          (ii) Shared power to vote or direct the vote: 0
          (iii) Sole power to dispose or direct the disposition:  0
          (iv) Shared power to dispose or direct the disposition of:  0
               

     

    CUSIP No. 68906L10513G/APage 9 of 10 Pages

     

    ACP has the power to dispose of and the power to vote the shares of Common Stock beneficially owned by it, which power may be exercised by its general partner, ACPGP.  ACA, as managing member of ACPGP, directs ACPGP's operations. Neither ACPGP nor ACA directly own any shares of Common Stock.  By reason of the provisions of Rule 13d-3 of the Securities Exchange Act of 1934 (the "Act"), ACPGP and ACA may be deemed to beneficially own the shares owned by ACP.
     
      B. Robert Atchinson and Phillip Gross
        (a) Amount beneficially owned:  0
        (b) Percent of class:  0%
        (c) (i) Sole power to vote or direct the vote:  0
          (ii) Shared power to vote or direct the vote:  0
          (iii) Sole power to dispose or direct the disposition:  0
          (iv) Shared power to dispose or direct the disposition:  0
               
    Messrs. Atchinson and Gross, as managing members of ACA, have shared power to vote the shares of Common Stock beneficially owned by ACP.  Neither Mr. Atchinson nor Mr. Gross directly own any shares of Common Stock.  By reason of the provisions of Rule 13d-3 of the Act, each may be deemed to beneficially own the shares beneficially owned by ACP.
     

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
      If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ý
       

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
      Not applicable.
       

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
      Not applicable.
       

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
      Not applicable.
       

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
      Not applicable.
       

     

    Item 10. CERTIFICATION  
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
       

     

    CUSIP No. 68906L10513G/APage 10 of 10 Pages

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: February 9, 2023

     

    ADAGE CAPITAL PARTNERS, L.P.
    By:  Adage Capital Partners GP, L.L.C.,
    its general partner
     
    By:  Adage Capital Advisors, L.L.C.,
    its managing member
     
    /s/ Robert Atchinson
    Name:  Robert Atchinson
    Title: Managing Member
     
    ADAGE CAPITAL PARTNERS GP, L.L.C.
    By:  Adage Capital Advisors, L.L.C.,
    its managing member
     
    /s/ Robert Atchinson
    Name:  Robert Atchinson
    Title: Managing Member
     
    ADAGE CAPITAL ADVISORS, L.L.C.
     
    /s/ Robert Atchinson
    Name:  Robert Atchinson
    Title: Managing Member
     
    ROBERT ATCHINSON
     
    /s/ Robert Atchinson
    ROBERT ATCHINSON, individually
     
    PHILLIP GROSS
     
    /s/ Phillip Gross
    PHILLIP GROSS, individually

     

     

     

     

    Get the next $OTIC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $OTIC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OTIC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Otonomy Announces Change in Stock Exchange Listing

      SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that the company's shares would be suspended from trading on Nasdaq effective at the open of business on December 23, 2022. Following such suspension, the company's shares will be traded on the OTC Pink Market. As previously reported, on November 14, 2022, Otonomy received a notice from Nasdaq indicating that the Listing Qualifications Staff (the Staff) had determined to delist the company's securities unless the company timely requested a hearing before the Nasdaq Hearings Panel (the Pan

      12/22/22 7:53:14 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Otonomy Provides Corporate Update

      SAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC) today announced that the company's board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution ("Plan of Dissolution") that would include the distribution of remaining cash to stockholders following an orderly wind down of the company's operations, including the proceeds from the sale of any pipeline assets. To reduce cost, Otonomy has implemented a reduction in workforce. These updates are discussed below. Evaluation of Strategic Options As previously reported, Otonomy initiated an evaluation of strategic options to realize value from its pipeline. The

      12/19/22 4:53:38 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Otonomy Reports Third Quarter 2022 Financial Results and Provides Corporate Update

      SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the quarter ended September 30, 2022 and provided an update on its product pipeline and corporate activities. Otonomy Program and Corporate Activity Updates In August 2022, Otonomy announced that OTO-313 demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints in a Phase 2 clinical trial in tinnitus patients. Based on these results, Otonomy discontinued development of OTO-313 and implemented other measures to extend its cash runway. Th

      11/10/22 4:05:00 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OTIC
    Financials

    Live finance-specific insights

    See more
    • Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update

      Top-line results for OTO-313 Phase 2 trial in tinnitus expected in August 2022; patient enrollment completed for clinical safety evaluation of higher and bilateral dosing of OTO-313 with top-line results expected in third quarter of 2022Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment completed for higher dose evaluation with top-line results expected in fourth quarter of 2022OTO-825 IND-enabling activities ongoing with IND filing expected first half of 2023Current capital funds operations through multiple clinical readouts Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biop

      7/25/22 4:05:00 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update

      SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter 2022 and provide a corporate update at 4:30 p.m. ET on July 25, 2022.  A live webcast of the call will be available online in the investor relations section of Otonomy's website at www.otonomy.com and will be archived there for 30 days. To access the live call by phone, please go to this link (registration link), and you will be provided with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minu

      7/18/22 7:30:00 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Otonomy Reports First Quarter 2022 Financial Results and Provides Corporate Update

      Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment ongoing for higher dose evaluationOTO-313 Phase 2 trial in tinnitus fully enrolled with top-line results expected in August 2022; clinical safety evaluation of higher and bilateral dosing ongoingOTO-825 IND-enabling activities ongoing with IND filing expected first half of 2023Current capital funds operations through multiple clinical readouts and into second half of 2023 Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, May 09, 2022 (GLOBE NEWSWIRE) --  Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today repor

      5/9/22 4:04:00 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OTIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Otonomy Inc. (Amendment)

      SC 13G/A - OTONOMY, INC. (0001493566) (Subject)

      2/14/23 4:06:58 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Otonomy Inc. (Amendment)

      SC 13G/A - OTONOMY, INC. (0001493566) (Subject)

      2/13/23 8:49:22 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Otonomy Inc. (Amendment)

      SC 13G/A - OTONOMY, INC. (0001493566) (Subject)

      2/10/23 4:29:37 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OTIC
    SEC Filings

    See more
    • SEC Form 15-12G filed by Otonomy Inc.

      15-12G - OTONOMY, INC. (0001493566) (Filer)

      4/4/23 3:40:49 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Otonomy Inc.

      EFFECT - OTONOMY, INC. (0001493566) (Filer)

      4/3/23 12:15:10 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Otonomy Inc.

      EFFECT - OTONOMY, INC. (0001493566) (Filer)

      4/3/23 12:15:09 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OTIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Hogan H Michael Iii

      3 - OTONOMY, INC. (0001493566) (Issuer)

      2/24/23 4:53:45 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Weber David Allen covered exercise/tax liability with 91,636 shares, decreasing direct ownership by 24% to 285,863 units (withholding obligation)

      4 - OTONOMY, INC. (0001493566) (Issuer)

      12/30/22 4:31:39 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Cayer Paul E covered exercise/tax liability with 40,054 shares, decreasing direct ownership by 18% to 183,733 units (withholding obligation)

      4 - OTONOMY, INC. (0001493566) (Issuer)

      12/30/22 4:30:19 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OTIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright reiterated coverage on Otonomy with a new price target

      HC Wainwright reiterated coverage of Otonomy with a rating of Buy and set a new price target of $5.50 from $10.00 previously

      3/1/21 8:38:28 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Otonomy with a new price target

      HC Wainwright & Co. reiterated coverage of Otonomy with a rating of Buy and set a new price target of $5.50 from $10.00 previously

      2/23/21 6:53:19 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler reiterated coverage on Otonomy with a new price target

      Piper Sandler reiterated coverage of Otonomy with a rating of and set a new price target of $5.00 from $10.00 previously

      2/22/21 3:01:01 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OTIC
    Leadership Updates

    Live Leadership Updates

    See more
    • Otonomy Appoints Jill Broadfoot to Board of Directors

      SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the appointment of Jill Broadfoot to its board of directors. "Jill is an excellent addition to the board with strong strategic, operational and financial expertise within the biopharmaceutical sector," said David A. Weber, Ph.D., president and CEO of Otonomy. "We are excited to welcome her as we continue our growth trajectory and make progress to achieving our clinical milestones." Since 2018, Ms. Broadfoot has served as chief financial officer (CFO) of aTyr Pharma, Inc., a biotherapeutics company. P

      8/19/21 7:30:00 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care